US FDA approves first AI tool for liver disease trials: How AIM-NASH transforms biopsy reading
A groundbreaking AI tool, AIM-NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologists in swiftly and accurately analyzing liver biopsies for MASH, a severe form of fatty liver disease. By quantifying fat, inflammation, and scarring, AIM-NASH promises to accelerate research and improve patient outcomes.
A groundbreaking AI tool, AIM-NASH, has received FDA approval to revolutionize liver disease drug trials. This innovative technology assists pathologists in swiftly and accurately analyzing liver biopsies for MASH, a severe form of fatty liver disease. By quantifying fat, inflammation, and scarring, AIM-NASH promises to accelerate research and improve patient outcomes.
